2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5208 Impact of molecular response on long-term survival and treatment outcomes in acute myeloid leukemia

Ameed Bawwab, MD, Emily C Zabor, PhD2, Lana Khatib3, Anas Odeh, MD4, Girahnaz Baloch, MD5, Moath Albliwi, MD6, Jessica El-Asmar, MD, MPH7, Yang Wang8, David Bosler, MD9, Akriti G Jain, MD, FACP10, John Carlos Molina, MD, MEd11, Abhay Singh, MD, MPH12, Aaron T. Gerds, MD, MS13, Sudipto Mukherjee, MD, PhD, MPH14, Ronald Sobecks, Professor of Medicine15, Anjali Sunder Advani, MD16, Hetty Carraway, MD, MBA17, Moaath Mustafa Ali, MD, MPH18
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
8 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
9 Cleveland Clinic Diagnostics Institute, Cleveland, Ohio, United States
10 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
11 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
12 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
13 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
14 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
15 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
16 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
17 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
18 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States

Background: Response assessment in acute myeloid leukemia (AML) is primarily based on morphologic evaluation according to the ELN 2022 criteria. While cytogenetic response has been shown to provide prognostic information (Hanna et al, AJH, 2025), the prognostic significance of molecular response (MR) to therapy has not been well studied.  

 

 Methods: We conducted a single-center retrospective study of AML patients (≥18 years) treated at Cleveland Clinic. Baseline variables included demographics, comorbidities, AML subtypes, cytogenetics & molecular features, next-generation sequencing (NGS), treatment responses, and follow-up data.  

 

Baseline molecular status was determined using the NGS study performed closest to diagnosis & was considered abnormal if any clinically significant mutation had a variant allele frequency (VAF) ≥5%; otherwise, it was classified as normal. MR at first-line assessment was categorized as: normal (all clinically significant mutations with VAF <5%); persistent (abnormal baseline with <50% reduction in VAF of any pathogenic mutation); partial molecular remission (≥50% reduction in VAF of all pathogenic mutations); gain (abnormal baseline with newly pathogenic mutations detected at response that were absent at baseline); or abnormal (normal baseline with newly detected clinically significant mutations with VAF ≥5%).  

 

Survival was estimated using the Kaplan-Meier method. Multivariable Cox regression was used to adjust for potential confounders. A 60-day landmark analysis was performed to account for the timing of MR assessment. Event-free survival (EFS) was defined from the 60-day landmark post-treatment initiation to refractory disease, relapse/progression, or death. Overall survival (OS) was defined from the 60-day landmark post-treatment initiation to death.  

 

Results: Among 1,017 patients with AML treated between 01/2015 and 01/2025, 825 underwent molecular profiling at diagnosis, of whom 150 also had profiling at first response assessment. Median age was 67 years; 55% were male & 85% were White. Among them, 53 (35%) achieved complete molecular remission (Abnl-Mo to Nl-Mo group), 18 (12%) achieved partial molecular remission (Abnl-Mo to Partial-Mo), 60 (40%) had persistent molecular abnormalities (Abnl-Mo to Persistent-Mo), 9 (6%) had gain of new pathogenic mutations (NL/Abnl-Mo to Gain-Mo), & 10 (6.7%) remained molecularly normal throughout (NL-Mo to NL-Mo group). The most common mutations were DNMT3A (32%), NPM1 (24%), TP53 (18%), RUNX1 (18%), & TET2 (17%).  

 

The CCR rates were significantly different across groups: 90% for NL-Mo to NL-Mo, 79% for Abnl-Mo to NL-Mo, 61% for Abnl-Mo to Partial-Mo, 50% for NL/Abnl-Mo to Gain-Mo, & 45% for Abnl-Mo to Persistent-Mo (P<0.01). On Multivariable logistic regression, Abnl-Mo to Persistent had lower odds of response compared to the NL-Mo to NL-Mo group (OR: 0.11, 95% CI: 0.01-0.71, P<0.05).  The 12-month cumulative incidence of transplant was lowest in the NL/Abnl-Mo to Gain-Mo (22%) & Abnl-Mo to Persistent-Mo (32%) groups, but differences were not statistically significant (P=0.1). Using a different analytic scheme, NL/Abnl-Mo to NL-Mo & Abnl-Mo to Partial-Mo had higher 12-month cumulative incidence of transplant (44% and 47%, respectively) than NL/Abnl-Mo to Persistent/Gain-Mo (30%) (P=0.04).  

 

The median follow-up for OS from landmarks was 26 months. The 12-month OS probabilities were 80% for the Abnl-Mo to NL-Mo, 70% for NL-Mo to NL-Mo, 67% for Abnl-Mo to Partial-Mo, 78% for the NL/Abnl-Mo to Gain-Mo, and 50% for Abnl-Mo to Persistent-Mo (log-rank P=0.04). Median OS was 49 months for Abnl-Mo to NL-Mo vs 16 months for Abnl-Mo to Persistent-Mo. Abnl-Mo to Persistent-Mo had increased hazard of death on multivariable analysis (HR: 1.07, 95% CI: 0.41-2.83) compared to NL-Mo to NL-Mo, but it was not statistically significant (P=0.4).  

 
Conclusion: MR at first assessment after frontline AML therapy is associated with clinical response, transplant receipt, & long-term survival. Complete molecular remission was associated with favorable outcomes. Findings should be interpreted cautiously because molecular profiling at response was not routine practice at our institution earlier, limiting sample size & statistical power. Nevertheless, these results support the clinical relevance of MR assessment in AML. Larger multicenter studies are needed to validate these findings and support incorporation of molecular response into future ELN response criteria. 

 

 

Ameed Bawwab, MD: No relevant conflicts of interest to declare.